Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. (Nasdaq: VIR) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed information on its clinical programs, collaborations and financial position. This SEC filings page aggregates those documents and pairs them with AI-generated summaries to help readers understand the key points in each filing.
For Vir Biotechnology, important filings include Form 8-K current reports describing material events, such as the license agreement with Norgine Pharma UK Limited for commercial rights to the tobevibart and elebsiran combination in chronic hepatitis delta across Europe, Australia and New Zealand, and updates on clinical data from the SOLSTICE Phase 2 trial. Other 8-K filings reference quarterly financial results, including cash, cash equivalents and investments, research and development spending, and progress across the ECLIPSE registrational program and oncology pipeline.
Investors following Vir Biotechnology’s infectious disease and oncology strategy can use this page to locate quarterly and annual financial disclosures, business updates reported via 8-K, and other SEC documents that discuss collaborations, licensing arrangements and clinical milestones. AI-powered tools highlight key terms, summarize complex sections and make it easier to identify information related to chronic hepatitis delta development, PRO-XTEN dual-masked T-cell engagers, and the company’s use of platforms such as dAIsY and PRO-XTEN.
The page also provides access to filings that may include details on revenue categories such as collaboration, contract, grant and license revenue, as well as information about material agreements and clinical trial updates referenced in attached press releases. Real-time integration with EDGAR means new Vir Biotechnology filings appear here as they are made public, with concise AI explanations to support faster review and comparison over time.
Vir Biotechnology, Inc. reported a net loss of $125.7 million for the quarter ended March 31, 2026, compared with a $121.0 million loss a year earlier, as it continued heavy investment in hepatitis delta and oncology programs. Total revenue was minimal at $(29) thousand, reflecting lower grant and collaboration activity.
Research and development spending was $108.9 million, driven by manufacturing and clinical costs for the ECLIPSE hepatitis delta program and dual-masked T-cell engagers. Cash, cash equivalents and investments totaled $809.3 million, helped by $162.3 million of net proceeds from a February follow-on equity offering. After quarter-end, Vir closed a major collaboration with Astellas around prostate cancer candidate VIR-5500, including a $240 million upfront payment and a $75 million equity investment.
Vir Biotechnology, Inc. reported a first quarter 2026 net loss of $125.7 million, or $0.85 per share, compared with a $121.0 million loss a year earlier. The company ended March 31, 2026 with $809.3 million in cash, cash equivalents and investments and completed a follow-on equity offering raising $172.5 million in gross proceeds.
Vir highlighted positive Phase 2 SOLSTICE data in chronic hepatitis delta, continued progress in its ECLIPSE registrational program, and advancement of its PRO-XTEN® dual-masked T-cell engager oncology pipeline, including the Astellas collaboration on VIR-5500 and dosing of the first patient in Phase 1 dose-expansion cohorts. Based on current plans and including expected Astellas proceeds, Vir now expects its cash resources to fund operations into the second half of 2028.
Vir Biotechnology, Inc. director Vicki L. Sato reported an open-market sale of 22,000 shares of common stock on May 1, 2026 at a weighted average price of $10.0466 per share.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025. After this transaction, she continues to hold 1,078,391 shares of Vir Biotechnology common stock directly.
Vir Biotechnology, Inc. director and President & CEO Marianne De Backer reported a restructuring of her common stock holdings. Two Form 4 transactions with code J reclassified a total of 467,064 shares at a stated price of $0.00 per share.
One entry moved 233,532 shares into indirect ownership held by the Ureel-De Backer Family Trust, where she and her spouse serve as trustees, following a transfer without consideration for tax and estate planning purposes. A parallel entry shows 233,532 shares under direct ownership, leaving her with 714,613 directly held shares and 286,650 indirectly held shares after these changes.
Issuer files a Form 144 notice relating to proposed resale of common stock. The filing lists 88,958 shares identified for sale on 04/30/2026, including option-derived lots of 65,625 and 23,333 shares. The filing also reports three open-market sales by Mark D. Eisner totaling 5,594 shares in February 2026 with proceeds shown.
Vir Biotechnology Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 9,257,235 shares of Vir Biotechnology common stock, representing 5.79% of the class. The filing shows sole dispositive power over 9,257,235 shares and sole voting power for 41,658 shares. Vanguard states these holdings reflect positions managed by Vanguard Portfolio Management LLC and affiliated business divisions, including securities held by Vanguard funds and certain client accounts. The filing is signed by a Vanguard official.
Vir Biotechnology has issued its 2026 definitive proxy for the virtual annual stockholder meeting on May 26, 2026, at 9:00 a.m. Pacific Time. Stockholders will vote on electing three Class I directors to terms ending in 2029, an advisory say-on-pay resolution on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor for 2026.
The company highlights strong governance practices, including an independent board chair, fully independent key committees and stock ownership guidelines. Its compensation program emphasizes pay-for-performance, with most executive pay at risk and tied to corporate achievements such as advancing the ECLIPSE Phase 3 program, publishing SOLSTICE Week 48 data, and progressing T-cell engager programs.
Vir Biotechnology, Inc. reported a leadership change in its medical organization. Executive Vice President and Chief Medical Officer Mark Eisner, MD, MPH has informed the company that he will step down from his role, effective April 24, 2026. The company has begun a search for a successor to oversee its clinical and medical strategy.
Vir Biotechnology, Inc. President and CEO Marianne De Backer had 72,559 shares of common stock automatically sold on 2026-04-06 at $9.156 per share. The footnotes state this sale occurred under a Rule 10b5-1 arrangement solely to satisfy the company’s tax withholding obligations related to vesting restricted stock units, and did not represent a discretionary trade by her.
After these transactions, she directly holds 948,145 shares of Vir Biotechnology common stock and indirectly holds 53,118 shares through the Ureel-De Backer Family Trust, where she and her spouse serve as trustees.